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Characterization of functional methylomes by
next-generation capture sequencing identiﬁes novel
disease-associated variants
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Maxime Caron1,2, John Lambourne1,2, Julie Lessard4, Karolina Tandre5, Åsa K. Hedman6,7, Tony Kwan1,2,
Bing Ge1,2, The Multiple Tissue Human Expression Resource Consortium**, Lars Ro¨nnblom5,
Mark I. McCarthy8,9,10, Panos Deloukas11,12, Todd Richmond13, Daniel Burgess13, Timothy D. Spector14,
Andre´ Tchernof4, Simon Marceau4, Mark Lathrop1,2, Marie-Claude Vohl3, Tomi Pastinen1,2
& Elin Grundberg1,2
Most genome-wide methylation studies (EWAS) of multifactorial disease traits use targeted
arrays or enrichment methodologies preferentially covering CpG-dense regions, to
characterize sufﬁciently large samples. To overcome this limitation, we present here a new
customizable, cost-effective approach, methylC-capture sequencing (MCC-Seq), for
sequencing functional methylomes, while simultaneously providing genetic variation
information. To illustrate MCC-Seq, we use whole-genome bisulﬁte sequencing on adipose
tissue (AT) samples and public databases to design AT-speciﬁc panels. We establish its
efﬁciency for high-density interrogation of methylome variability by systematic comparisons
with other approaches and demonstrate its applicability by identifying novel methylation
variation within enhancers strongly correlated to plasma triglyceride and HDL-cholesterol,
including at CD36. Our more comprehensive AT panel assesses tissue methylation and
genotypes in parallel at B4 and B3M sites, respectively. Our study demonstrates that
MCC-Seq provides comparable accuracy to alternative approaches but enables more efﬁcient
cataloguing of functional and disease-relevant epigenetic and genetic variants for large-scale
EWAS.
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D
NA methylation is an epigenetic modiﬁcation that was
previously thought to be important only for gene
silencing through hypermethylation of CpG islands in
promoter regions; however, recent studies have revealed more
diverse functions dependent on genomic location1. For instance,
hypermethylation within the gene bodies is likely to be indicative
of primed expression and is associated with increased gene
expression2,3. Proﬁling of histone modiﬁcations by chromatin
immunoprecipitation and high-throughput sequencing (ChIP-
Seq) has uncovered strong correlations between chromatin
structure and DNA methylation, with hypomethylated regions
associated to active marks or open chromatin and
hypermethylated regions suggestive of repressed regulatory
regions and heterochromatin2. H3K4me3, known to mark
nucleosomes ﬂanking transcription start sites and CpG-rich
promoters, is negatively associated with DNA methylation,
whereas distal regulatory elements (that is, enhancers) marked
by H3K4me1 are relatively CpG poor with a more variable
hypo- to hemimethylated proﬁle3. As the majority of approaches
assessing the human methylation landscape have been biased to
CpG-rich regions3, the methylation pattern of enhancers remains
to be described in more detail.
Other investigated features of DNA methylation variation in
human populations include the effects of environmental4 and
genetic factors3,5, and the role of methylation in complex disease
susceptibility6–8. We recently estimated methylation levels of
B450,000 CpGs in subcutaneous adipose tissue (AT) across 648
female twins and identiﬁed common sequence variants that
contribute signiﬁcantly to methylation variability, with
indications that some of these variants may also mediate
genetic risk for metabolic diseases3 possibly through changes in
methylation levels. We further noted that in these variables,
disease-linked methylation sites are enriched in distal regulatory
elements, paralleling earlier ﬁndings of common sequence
variants identiﬁed in genome-wide association studies (GWAS)
being enriched in active chromatin measured by DNaseI
hypersensitivity9 or within tissue-speciﬁc enhancer marks10. In
addition, the most comprehensive study to date of methylation
proﬁles across multiple tissues also highlighted that enhancers
contain tissue-speciﬁc variable CpGs that co-localize with tissue-
speciﬁc transcription factors11.
However, the majority of methylation quantitative trait loci
(QTL) and epigenome-wide association studies (EWAS) pre-
sented to date have used the Illumina Human Methylation 450
BeadChip array (Illumina 450K array). Although covering
B480,000 CpGs in the human genome, the Illumina 450K array
is biased towards regions with high CpG content such as
promoters, which we and others have demonstrated to have
limited inter-individual and inter-tissue variation3,11. Largely due
to the invariable state of promoter-located CpGs, these
regions are also known to be depleted among signiﬁcant
disease-associated sites3. Importantly, tissue-speciﬁc and
disease-relevant regions such as enhancers are greatly
underrepresented on the Illumina 450K array.
In contrast to available targeted methodologies12 or alternative
sequencing methods biased towards CpG-dense regions such as
reduced representation bisulﬁte sequencing (RRBS) or methylated
DNA immunoprecipitation, whole-genome bisulﬁte sequencing
(WGBS) allows complete characterization of the methylation
landscape. However, with only B20% or less of CpGs being
variable across individuals or tissues11, WGBS is inefﬁcient for
large-scale population studies, as it has a high cost and requires
in-depth sequencing capacity to achieve sufﬁcient coverage. Thus,
none of the above methods are optimal for comprehensive studies
of methylation variation and their impact on complex diseases.
Alternative approaches to interrogate functional (that is,
regulatory active) methylomes are needed for more
comprehensive yet cost-effective identiﬁcation of biologically
relevant CpGs associated to complex diseases.
Here, we present methylC-capture sequencing (MCC-Seq), a
next-generation sequencing capture approach interrogating
functional methylomes in disease-targeted tissues or cells. We
design AT-speciﬁc panels to probe up to B4.5 106 putative
functional DNA methylation sites as deﬁned by their localization
to hypomethylated footprints and regulatory elements, as well as
B2.8 106 single-nucleotide polymorphisms (SNPs) for simul-
taneous genotyping proﬁling. We validate the method through
comparisons with WGBS, Illumina 450K array and Agilent
SureSelect Human Methyl-Seq (Agilent SureSelect) data, and
show that MCC-Seq yields comparable resolution over targeted
intervals. We demonstrate the ability of MCC-Seq to identify
novel biologically relevant epigenetic variants associated to
disease by applying the panel in a disease–trait association study
of 72 individuals. Our initial results illustrate the advantages of
this new approach over currently used methods for methylome
analysis, providing a viable alternative for powerful and
cost-effective large-scale interrogation of functional methylomes.
Results
First-generation capture panel design for MCC-Seq. Using
human AT as a model, we designed a ﬁrst-generation sequence
panel to capture the putative functional and disease-linked
methylome in AT (Met V1) (Table 1 and Methods). We targeted
87Mb of sequence comprising (1) hypomethylated footprints,
generated from WGBS data of 30 AT samples, (2) regulatory
elements (identiﬁed by H3K4me1 and H3K4me3 ChIP-Seq)
in human adipocytes characterized by the NIH Roadmap
Epigenomics Mapping Consortium and (3) B50K CpGs with
known association to metabolic phenotypes3 (Supplementary
Data 1). All together, the panel targets 2,496,975 unique CpGs
with 210,883 directly overlapping Illumina 450K array-targeted
CpGs. By including both putative enhancer and promoter
regions, we aimed to obtain a more complete proﬁle of
AT-speciﬁc regulatory regions and to investigate the variability
status of these CpGs at increased depth over previous studies3.
In MCC-Seq, a whole-genome sequencing library is prepared,
bisulﬁte converted and ampliﬁed, followed by a capture enriched
for targeted bisulﬁte-converted DNA fragments (Methods). This
is achieved through the novel SeqCap Epi probe design platform
by Roche NimbleGen, which enables capture of double-stranded
targets regardless of their methylated state via high tiling density
of probes. To test the efﬁciency and performance of Met V1, we
performed targeted enrichment of both uniplex (1-plex) and
multiplexed library samples (2-plex, 4-plex, 6-plex and 10-plex).
Each capture was sequenced on a single lane of the 100 bp paired-
end Illumina HiSeq2000/2500 System. Generated reads were
Table 1 | Composition of Met V1 and Met V2 panels.
Panel components Met V1 Met V2
AT-hypomethylated footprints CpGs (N) 1,089,355 2,683,904
AT-regulatory elements (H3K4me1 and me3)
CpGs (N)
1,625,328 1,625,328
Illumina 450K CpGs (N) 210,883 482,421
Metabolic trait-associated SNPs (N) — 28,947
Core SNPs (N) — 256,327
Total covered regions (Mb) 87.0 156.2
Total covered CpGs (N) 2,496,975 4,442,383
Total covered SNPs (N) 1,343,928 2,840,815
SNP, single-nucleotide polymorphism.
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aligned to the converted reference genome using BWA v.0.6.1
(ref. 13) and ﬁltered according to our benchmark bioinformatics
workﬂow (Methods) using a read depth cutoff per CpG of Z5X.
The sequence statistics obtained for the different captured
pooled samples are summarized in Supplementary Table 1. The
average on-target CpG read depth ranged from 13X (10-plex) to
82X (1-plex) and the percentage of total reads that mapped within
the target CpGs averaged 62% (ranging from 51% to 80%), and
was independent of the degree of multiplexing. The average
number of targeted CpGs with Z5X depth of sequence coverage
decreased with increasing multiplexing from 94% (1-plex) to 63%
(10-plex) of targeted CpGs (Supplementary Table 1).
Second-generation panel design for comprehensive proﬁling.
Based on the performance of the ﬁrst AT-speciﬁc panel, we
developed and assessed a comprehensive second-generation
AT MCC-Seq panel (Met V2) that encompasses additional
AT-speciﬁc regulatory regions and variants, and additional SNPs
throughout the genome for simultaneous methylation and genetic
association studies (Table 1 and Methods). The Met V2 panel
targets 156Mb of sequence spanning 4,442,383 unique CpGs and
2,840,815 autosomal biallelic SNPs from dbSNP 137. The regions
covered by the Met V2 panel include the following: (1) CpGs
contained within low (LMRs) and unmethylated regions (UMRs)
identiﬁed from merged data sets of 30 WGBS AT samples
(Supplementary Data 2); (2) CpGs located within human
adipocyte regulatory elements (H3K4me1 and H3K4me3) from
the NIH Roadmap Epigenomics Mapping Consortium; (3) all
482,421 CpGs from the Illumina 450K array; (4) 28,947 regions
covering metabolic disease-associated GWAS loci from the
National Human Genome Research Institute GWAS catalogue (9
January 2014); and (5) the 256,327 SNPs from the Illumina
HumanCore BeadChip.
To assess the performance of the larger Met V2 panel, we
applied the MCC-Seq protocol and performed targeted enrich-
ment on a 6-plex capture. Sequencing was conducted on one lane
of the 100-bp paired-end Illumina HiSeq2000/2500 System. On
average, 62% of the reads mapped to target regions with 15X
mean coverage and 65% of the target regions were covered at a
sequence depth of Z5X (Supplementary Table 2).
Sample-based validation of MCC-Seq. As a ﬁrst validation step,
we assessed the effects of technical variability on methylation
proﬁles by comparing the results obtained from a single DNA
sample derived from visceral AT (VAT) prepared in replicate
experiments with independent captures on the same panel (Met
V1) and different degrees of multiplexing (4-plex versus 10-plex).
We found a high concordance of the methylation calls for over-
lapping CpGs (N¼ 1,587,026; average coverage4-plex¼ 36X;
average coverage10-plex¼ 30X; R¼ 0.98; Pearson’s correlation is
used throughout; Fig. 1a). We also assessed technical variability of
the methylation calls by comparing the results from a different
DNA sample prepared in replicate experiments with independent
captures using the two different panels and different degrees
of multiplexing (Met V14-plex versus Met V26-plex), and
conﬁrmed the high concordance in methylation calls for
CpGs (N¼ 1,569,170; average coverageMetV1(4-plex)¼ 16X; average
coverageMetV2(6-plex)¼ 30X; R¼ 0.97; Fig. 1b).
Next, we compared MCC-Seq methylation with WGBS data
from the same sample. Here we also found a high correlation
(MCC-Seq versus WGBS) for overlapping CpGs (N¼ 1,620,874;
average coverageMCC-Seq¼ 31X; average coverageWGBS¼ 23X;
R¼ 0.97; Fig. 1c). In addition, we evaluated the sequence results
against the Illumina 450K array data on the subset of these
CpGs that are included in the array by comparing this method
against both MCC-Seq and WGBS. For both comparisons,
we obtained correlations of R¼ 0.96 (N¼ 150,898; average
coverageMCC-Seq¼ 32X; average coverageWGBS¼ 23X; Fig. 2 and
Supplementary Table 3). To rule out any biases in the
comparisons, we also restricted the correlations to CpGs with
intermediate methylation levels by excluding completely
hypo- (0%) and hypermethylated (100%) CpGs based on the
WGBS and MCC-Seq data. Encouragingly, we found the high
correlation being maintained with R¼ 0.95 (N¼ 45,097; average
coverageMCC-Seq¼ 33X) and R¼ 0.94 (N¼ 45,097; average
coverageWGBS¼ 25X) for MCC-Seq versus Illumina 450K and
WGBS versus Illumina 450K, respectively (Supplementary Fig. 1).
Using this limited set of CpGs proﬁles across multiple approaches
we were also able to conﬁrm the importance of generating
sufﬁcient sequence depth for accurate methylation calls, as
correlation was shown to improve with increased read-depth
cutoffs (Supplementary Table 4). Similar improvement in
correlations of methylation calls by MCC-Seq and Illumina
450K was seen with increasing read depth (Supplementary Fig. 2).
Finally, we contrasted methylation calls from MCC-Seq against
Agilent SureSelect—another targeted-sequencing approach based
on a different methylation capture strategy than described here,
allowing only single-strand capture of smaller target regions,
and thus not suitable for comprehensive genotype proﬁling.
More speciﬁcally, MCC-Seq relies on the efﬁcient capture of
targeted methylated and unmethylated CpGs (up to 160Mb or
4.4M CpGs) in bisulﬁte-converted libraries, whereas Agilent
SureSelect captures target regions before bisulﬁte conversion
and requires larger amounts of input DNA. By juxtaposing
both capture approaches using the same sample sequenced
at extreme depth, we obtained correlations that mimic those
of our technical replicates shown above (N¼ 2,551,186;
average coverageSureSelect¼ 137X; average coverageMCC-Seq¼ 216X;
R¼ 0.99; Supplementary Fig. 3A). This high correlation
(N¼ 1,734,371; average coverageSureSelect¼ 156X; average
coverageSureSelect¼ 230X; R¼ 0.99; Supplementary Fig. 3B) was
also seen when excluding completely hypo- (0%) and hyper-
methylated (100%) CpGs in both approaches, indicating accuracy
in measurement for CpGs with intermediate methylation levels as
shown above.
Population-based validation of MCC-Seq. We then applied
MCC-Seq Met V1 to a set of 72 VAT samples derived from obese
individuals (body mass index (BMI) 440 kgm 2) aged 19–67
years, undergoing bariatric surgery and diagnosed with or with-
out metabolic syndrome14 (Methods). Metabolic syndrome was
diagnosed when individuals had abdominal obesity and at least
two of the following four criteria set by the National Cholesterol
Education Program Adult Treatment panel III15: elevated plasma
fasting glucose, high triglyceride (TG) levels, high blood pressure
or lower high-density lipoprotein cholesterol (HDL-C) levels.
Using the 4-plex pooling approach, we sequenced the samples to
an average read depth of 25X for on-target CpGs. At a sequence
depth ofZ5X, a total of 2,147,576 CpGs were detected in at least
one individual, with 1,882,222 (88%) CpGs detected in at least
50% of the samples. In all subsequent population-based analyses,
we required Z5X coverage based on our comparisons described
above (Supplementary Fig. 2). In addition to requiring Z5X
coverage, we eliminated CpGs that had low coverage, by removing
those that were below the 20th percentile for averaged coverage
over the 72 samples for the distribution across all CpGs. This
yielded 1,710,209 CpGs for further consideration (Supplementary
Fig. 4 and Methods) with an average sequence depth of 30X and a
minimum of 18X. An outline of all population-based analyses is
shown in Supplementary Fig. 5.
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First, we characterized the methylation pattern of these 1.7M
CpGs assessed within 72 AT samples and noted that, as expected,
the majority (69%) of the captured CpGs exhibited a hypo-
methylated pattern (deﬁned as o20% methylation) with only
17% being hemi- to hypermethylated (deﬁned as 450%
methylation; Supplementary Fig. 6). We also characterized these
CpGs by assessing their genomic localization within putative
regulatory regions through their overlap with histone marks
(H3K4me1 and H3K4me3) in human adipocytes and hypo-
methylated footprints from our WGBS on 30 AT samples
(Methods). To do this, we ﬁrst characterized hypomethylated
footprints by distinguishing between LMRs and UMRs in
the WGBS data as previously described16 (Methods and
Supplementary Data 2). We noted that LMRs were associated
with CpG-poor distal regulatory regions (average methylation
level of 24%), whereas UMRs are CpG-dense and mapped
principally to promoter regions (average methylation level of 9%;
Supplementary Fig. 7). For the regulatory elements overlapping
H3K4me3 marks (active promoters), we restricted our analysis to
locations within 1 kb of transcription start sites of known RefSeq
transcripts and not overlapping H3K4me1 marks as previously
described3. We then assessed the population variability of
methylation levels for CpGs mapping to H3K4me1 marks or
LMRs (putative enhancers) and compared this with similar
estimates of methylation variation for CpGs mapping to
H3K4me3 marks or UMRs (putative promoter regions). As
previously reported3, methylation of CpGs that map to enhancer
elements are more variable across individuals (median s.d.¼ 9.4),
whereas promoter regions display a more invariable pattern
(median s.d.¼ 1.5; Supplementary Fig. 8).
We then proﬁled a subset (N¼ 24) of the 72 VAT samples
(Supplementary Fig. 5) with the Illumina 450K array, for direct
comparisons of methylation scores estimated by the two methods
when considering multiple samples. We applied a normalization
method on the Illumina 450K array data to reduce technical
biases that have been shown to have an impact on the b-values17
(Methods). The average correlation of methylation levels
estimated by the two methods was R¼ 0.50 and R¼ 0.58,
respectively, for the top 25% (N¼ 34,517, median s.d.¼ 11.0)
and top 10% (N¼ 13,807; median s.d.¼ 13.6) most variable CpGs
in the MCC-Seq data based on s.d. estimates of each CpGs
(Supplementary Fig. 9). These population-based correlations of
MCC-Seq versus the Illumina 450K array are noticeably lower
than the sample-based correlations described above; however,
given the different nature of the comparisons, that is, correlation
of the methylation measurements at each CpG in multiple
individuals here versus the overall correlation across all CpGs
within a single sample, they cannot be directly compared. As
such, we ﬁnd that the sample-based correlations across the 24
samples are similar to that described above for a single sample,
ranging from R¼ 0.93 to 0.96.
Population-based genotype proﬁling by MCC-Seq. The same
24 AT samples described above were also genotyped with the
Illumina HumanOmni2.5S-8 BeadChip array for validation of
MCC-Seq’s ability to simultaneously call genotypes. After
stringent quality control, we obtained SNP genotypes at 94,600
overlapping loci using MCC-Seq (Met V1) (Methods). We
observed 99% genotype concordance between the two methods at
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sites on the SNP array, indicating that MCC-Seq has the potential
to allow for simultaneous and accurate genotyping calling over
regions of interest. Similarly, comparing the observed hetero-
zygosity from the two measurements yielded high correlation
(Supplementary Fig. 10).
In total and based on dbSNP 137, we determined that the Met
V1 panel has the potential to detect 1,343,928 autosomal biallelic
SNPs within its target regions, of which an average of 1,300,369
(97%) per sample were covered at a read depth of Z5X. In the
broader Met V2 panel, there is a heightened potential for
autosomal biallelic SNP detection (2,840,815) with an average of
2,666,458 (94%) SNPs detected per sample at 5X read coverage.
Thus, the performance of the Met V2 panel is similar to that of
the V1 panel, despite its more extensive coverage (forexample,
156 versus 87Mb).
EWAS of TG levels using MCC-Seq. To illustrate the application
of MCC-Seq for epigenome mapping of a quantitative trait, we
examined plasma TG levels measured on the 72 individuals for
which the MCC-Seq Met V1 data were available. We note that
TG exhibits substantial individual variability in the study cohort
(Supplementary Fig. 11). To assess associations, we applied a
generalized linear model (GLM) assuming a binomial distribution
of methylation levels and adjusting for BMI, age and biological
sex along with the sequence depth at each CpG. We assigned a
nominal signiﬁcance for the trait association using a permutation
test (Methods). We identiﬁed 2,580 CpGs with P-value r0.001
(Supplementary Data 3) and 518 CpGs with P-value r0.0001.
The locations of these potential TG-associated CpGs were
evaluated with respect to putative regulatory regions through
their overlap with histone marks (H3K4me1 and H3K4me3) in
human adipocytes, and LMRs and UMRs identiﬁed as described
above (Methods). As shown in Fig. 3a, TG-associated CpGs
(Pr0.001) were found to map preferentially to H3K4me1
(enhancer) histone marks and/or LMRs (Fisher’s exact test
P¼ 5.3 10 7). This pattern was even more pronounced when
information on LMRs unique to AT and H3K4me1 peaks was
combined (Methods) to demarcate putative enhancers (Fisher’s
exact test P¼ 6.0 10 10). This supports the mounting evidence
that disease–trait-associated epigenetic variants localize, to a large
extent, to distal regulatory regions. Similar results were also
observed when restricting the analysis to CpGs that met the more
stringent criterion of Pr0.0001 in the permutation test (Fig. 3a).
Furthermore, at both P-value cutoffs, we observed depletion of
TG-associated CpGs within putative promoter regions that are
shared across tissues as detected by either H3K4me3 histone
marks or UMRs (Fisher’s exact test P¼ 7.1 10 10) versus
enrichment when restricting to promoter marks unique to AT
(Fisher’s exact test P¼ 2.4 10 3; Fig. 3b).
We further examined the subset of MCC-Seq TG-associated
CpGs that overlapped nearby (250 bp ﬂanking the CpG) CpGs
from the Illumina 450K array used in an independent cohort of
B650 female individuals from the MuTHER study3 with TG
measurements and AT samples available. MuTHER is a
population-based cohort study that includes female twins
(1/3 dizygotic and 2/3 monozygotic) aged 38.7–84.6 years
recruited from the TwinsUK resource18, which has previously
been shown to be comparable to population singletons in terms of
disease-related and lifestyle characteristics19. Methylation data on
AT samples from the study members that were previously
proﬁled on the lllumina 450K array were tested for association
with TG levels using a linear mixed model similar to the above
but also incorporating familial relationship, twin zygosity and
other cofactors (Methods). We selected the top TG-associated
MuTHER CpGs within the 250 bp of the 2,580 tested CpGs
identiﬁed at Pr0.001 (Supplementary Data 3), revealing 1,582
Illumina 450K array CpGs. Of these, 124 (8%) were found to be
signiﬁcantly associated with TG (Bonferroni P-value threshold of
P¼ 0.05; nominal P-value: 0.05/1,582¼ 3.2 10 5) in the
MuTHER data with the same direction of effect as observed in
our study (8.9-fold enrichment; binomial test, Po2.2 10 16).
Encouragingly, the replication was strengthened when limiting
to Illumina 450K array CpGs directly overlapping the 2,580
TG-associated MCC-Seq CpGs with 18 out of 171 sites (11%)
signiﬁcantly associated in MuTHER with the same direction of
effect as in MCC-Seq results (18.0-fold enrichment; binomial test,
Po2.2 10 16).
Assessment of loci harbouring TG-associated CpGs. We further
annotated the most signiﬁcant TG-associated CpGs (Pr0.0001)
mapping to an AT-speciﬁc regulatory element (N¼ 89; Fig. 3) in
further detail (Supplementary Data 4). First, we assessed their
association to TG in the larger MuTHER cohort as described
above. In total, 33/89 TG-associated CpGs overlapped a nearby
Illumina 450K-measured CpG (250 bp ﬂanking the CpG) and
were included in the analysis. Here, 21% were found to also be
signiﬁcantly associated with TG in the MuTHER cohort, with
the same direction of effect using the stringent Bonferroni
P-value threshold of P¼ 0.05 as estimated above; nominal
P-value¼ 3.2 10 5. Furthermore, using the nominal P-value of
0.05 and the same direction of effect, as many as 16 CpGs (48%)
showed evidence of association to TG in the independent cohort
(Supplementary Table 5).
We recently showed high degree of sequence dependency of
AT DNA methylation and thus also examined the potential
existence of genetic regulation among the TG-associated CpGs
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Figure 3 | Annotation of TG-associated CpGs in putative regulatory
regions. CpGs with average reads coverage above the 20th percentile that
showed evidence of association with TG (Pr0.001 or Pr0.0001) were
annotated with additional data. (a) This panel shows signiﬁcant enrichment
(y axis, fold-change) of TG-associated CpGs for Pr0.001 (orange bars)
and Pr0.0001 (grey bars) within putative enhancer regions as deﬁned by
H3K4me1 marks and/or LMRs (***P¼ 5.3 10 7 for Pr0.001 and
P¼4.9 10 5 for Pr0.0001 CpGs, respectively), and for H3K4me1
marks and/or LMRs unique to AT (***P¼ 6.0 10 10 for Pr0.001 and
P¼4.1 10 7 for Pr0.0001 CpGs, respectively). (b) This panel shows
signiﬁcant depletion (y axis, fold-change) of the same TG-associated CpGs
signiﬁcance (Pr0.001 shown as orange bars and Pr0.0001 shown as
grey) within putative promoter regions as demarcated by H3K4me3 marks
and/or UMRs (***P¼ 7.1 10 10 for CpGs with Pr0.001 and *P¼0.023
for CpGs with Pr0.0001), but enrichment when restricting to H3K4me3
marks and/or UMRs unique to AT (**P¼ 2.4 10 3 for CpGs with
Pr0.001 and *P¼0.020 for CpGs with Pr0.0001). Enrichment was
established using Fisher’s exact test.
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using our publicly available cis-mQTL data from AT proﬁled on
the Illumina 450K array3. Again, we used the 33 CpGs that
overlapped a nearby Illumina 450K as described above. We found
that methylation levels of 55% of these TG-associated CpGs
are regulated by a nearby SNP at 1% false-discovery rate3
representing twofold enrichment (Fisher’s exact test
P¼ 0.0017), indicating that a large proportion of trait-
associated epigenetic variants identiﬁed here are under genetic
control (Supplementary Table 5).
Next, we used transposase-accessible chromatin sequencing
(ATAC-Seq), as detailed in the Methods, on adipocyte nuclei
isolated from AT of an obese individual undergoing bariatric
surgery, to further pinpoint and ﬁne-map the effects of the
TG-associated CpGs linked to hypomethylated footprints.
ATAC-Seq20 is an antibody-independent method for proﬁling
active regulatory regions by mapping open chromatin with
sensitivity that is comparable to DNaseI-Seq but with the
advantage of requiring only B100,000 input cells. Here we
found that 65/89 CpGs (73%) were nearby (within 250 bp) or
directly overlapping an ATAC-Seq peak, indicating that these
CpGs could be mapped with high conﬁdence to active regulatory
regions in pure adipocytes.
We further examined the expression pattern of genes in the
vicinity of our top CpGs in human adipocytes compared with
various blood cell types (Methods). Candidate genes were
identiﬁed as overlapping or within 100 kb of the TG-associated
CpGs. We performed RNA sequencing (RNA-Seq) of adipocyte
nuclei isolated from visceral and subcutaneous AT of four obese
individuals undergoing bariatric surgery matching our discovery
cohort, as well as from B cells, T cells and monocytes of four
healthy donors (Methods). Differential expression analysis
(Methods and Supplementary Data 5) revealed 38/76 CpGs
(50%) being associated with genes signiﬁcantly more expressed in
adipocytes (when comparing both visceral- and subcutaneous-
derived expression, log2 fold change42, Po0.05) which is a
signiﬁcant enrichment of adipocyte-speciﬁc expression (1.6-fold,
Fisher’s exact test, P¼ 6.6 10 4).
We also examined the overlap of our potential TG-associated
loci with the National Human Genome Research Institute
catalogue of results from GWAS (accessed January 2014) and
found that genes linked to 19 (23%) of our CpGs were previously
cited for a metabolic disease trait based on GWAS (1.5-fold
enrichment; Fisher’s exact test, P¼ 0.06; Supplementary Data 5).
These genes include CD36 (HDL-C), RPTOR (obesity) and
ABCG5/ABCG8 (low-density lipoprotein cholesterol (LDL-C) and
total cholesterol). Additional follow-up data on CD36 is provided
below.
Follow-up of the TG-associated loci mapping to CD36. To
illustrate these results, we selected the most signiﬁcant CpG
of the TG-associated loci for additional follow-up studies
(chr7:80,276,086-80,276,087; GLM P¼ 1.1 10 9; Fig. 4 and
Supplementary Data 4). This CpG is located within an intragenic
region of CD36, a gene encoding a glycoprotein with an impor-
tant role in lipid metabolism21,22 that has been linked to
metabolic disease susceptibility23. Levels of circulating CD36
protein were recently reported to be positively correlated to
plasma TG levels in obese individuals24 and SNPs near the gene
were associated to HDL-C levels in a large GWAS25. The
TG-associated CpG maps to an LMR unique to AT. Using
RNA-Seq data generated from both human adipocytes derived
from obese individuals and blood cells from healthy controls as
described above (Supplementary Data 5), we found signiﬁcantly
higher CD36 expression in adipocytes than in blood cells (GLM,
log2 fold change¼ 2.4–11.0, P¼ 6.3 10 22–3.3 10 161). In
an attempt to study whether the potential enhancer region where
the TG-associated CpG maps controls expression of CD36, we
used our publicly available array-based expression
(IlluminaHT12) and methylation (Illumina 450K array) data
from the MuTHER cohort (NB650)3. We found that
methylation of the closest Illumina 450K array CpG
(cg05917188; Fig. 4) was negatively associated with expression
of the main CD36 transcript in AT (linear mixed model,
P¼ 2.4 10 5), highlighting a gene regulatory effect of our
TG-associated hypomethylated region. Finally, we also used the
MuTHER cohort (NB650) and cg05917188 as described above,
for validation of the TG association where we were able to verify
the pronounced effect of methylation at the regulatory region on
TG levels (linear mixed model, P¼ 3.2 10 7; Fig. 4 and
Supplementary Table 5). As recent GWAS efforts show links to
HDL-C, we also tested for this association to CpG methylation
within our discovery cohort and found a similar pattern (GLM,
P¼ 2.93 10 5) with concordant results from the MuTHER
cohort (linear mixed model, P¼ 1.8 10 3; Fig. 4).
Taken together with the other results described above, our data
provide strong evidence in favour of an epigenetic effect of the
AT-speciﬁc regulatory region of CD36 on multiple metabolic
disease-related traits.
Discussion
The assessment of DNA methylation has emerged as an essential
tool for understanding the aetiology of human disease26. Recent
reports show that variable and functional epigenetic variants are
enriched in enhancers, rather than in promoter and CpG island
regions3, which are the principal regions assayed by commonly
used targeted approaches (for example, Illumina 450K array and
RRBS). Although WGBS is comprehensive, it is inefﬁcient for the
large-scale investigations that are required for methylation QTL
studies and EWAS of common multifactorial diseases. This
motivated us to look for an improved method for high-resolution
interrogation of the variable functional component of the
methylome.
We established MCC-Seq to assess target regions of the
genome in a cost-effective and accurate manner. With MCC-Seq,
we can examine active regulatory regions in disease-appropriate
tissues, speciﬁcally permitting us to identify disease-linked DNA
methylation variants that are not identiﬁable with previous
targeting approaches. MCC-Seq can include up to 200Mb in
custom, user-deﬁned interrogation panels, which is an advantage
over other available capture approaches. Samples can be multi-
plexed to obtain lower sequencing costs for large-scale EWAS.
Although upfront analysis time is needed for proper selection of
CpGs, the customizable and ﬂexible design allows easy elimina-
tion of CpGs that are invariable across individuals11, providing
further savings at the sequencing and computational levels. As an
example, our Met V2 adipose-speciﬁc panel covers B4.5 106
CpGs in regulatory regions and also includes the complete
Illumina 450K panel ofB480,000 CpGs, allowing comparisons or
replication with studies that use the latter. We also demonstrate
the capacity for multifunctional assays providing both
comprehensive methylome and SNP genotype data, thereby
permitting additional data integration than in other techniques
such as Agilent SureSelect where single-strand capture bias
inhibits complete genotype proﬁling. As such, the Met V2 panel
includes the complete set of SNPs from the Illumina HumanCore
BeadChip, which covers highly informative genome-wide tag
SNPs found across globally diverse populations, allowing for
further high-density genotype imputation.
Comparisons of MCC-Seq to three alternative approaches—
WGBS, Illumina 450K array and Agilent SureSelect—indicated
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that methylation calls derived from MCC-Seq correlated highly
with all three methods (for example, R40.96) with Illumina 450K
array showing slightly lower correlation. The lower correlation of
MCC-Seq and WGBS with the Illumina 450K array data may be
attributable to technical differences in DNA methylation assess-
ment (that is, microarray versus next-generation sequencing) and
proabably higher speciﬁcity of methylation proﬁles called from
sequencing methods at sufﬁcient depth. Overall, we believe that
MCC-Seq with its larger ﬂexible platform, genotyping ability and
low DNA input requirements, is more adapted to large-scale
EWAS studies than other studied approaches.
Based on our results, we predict that MCC-Seq will be
particularly valuable for the identiﬁcation of functional, disease-
linked DNA methylation variants. In fact, we demonstrated the
potential of such an approach by applying an AT-speciﬁc panel to
a cohort of 72 individuals in which we had measured metabolic-
related traits, including TG. In agreement with the current
literature, the analysis of the TG-associated CpGs revealed a clear
signiﬁcant enrichment within putative enhancer regions as
deﬁned by hypomethylated regions and adipocyte-speciﬁc
ChIP-Seq data (NIH Roadmap Epigenomics Mapping
Consortium) and a clear underrepresentation within putative
tissue-independent promoter regions. This demonstrates the
importance of investigating putative enhancer regions for
functional epigenetic variant identiﬁcation—regions currently
underrepresented in the commonly used Illumina 450K array and
RRBS approaches. When comparing the subset of results from
MCC-Seq that were available from the Illumina 450K array data
on the large MuTHER/TwinsUK cohort of 650 female twins3, we
found a signiﬁcant overlap of CpGs exhibiting signiﬁcant TG
association in the two data sets, further validating MCC-Seq as a
tool for powerful discovery of trait-associated methylation
variation.
Additional investigations were performed for the most
signiﬁcant TG-associated CpG mapping to a regulatory region
within CD36, which is known to function in fatty acid and
glucose metabolism21,22. Here we were not only able to validate
the results in the MuTHER resource showing consistent direction
of effect of the association of methylation variation in the
regulatory region with TG but also show evidence of regulation of
CD36 expression by our identiﬁed AT-speciﬁc regulatory region
at the population level. These results of a potential AT regulation
of CD36 expression were further strengthened by RNA-Seq data
of puriﬁed adipocytes and multiple blood cell types showing
pronounced difference in the expression pattern with adipocytes
expressing CD36 at considerably higher level. As our discovery
cohort included obese individuals diagnosed with or without
metabolic syndrome, we also tested another trait used for the
diagnosis, HDL-C, in association with DNA methylation at our
CpG of interest. Interestingly, we noted a similar association to
HDL-C, which was further validated in the MuTHER cohort,
indicating that epigenetic variants of CD36may be able to serve as
a biomarker for cardiovascular disease prediction in obese
individuals similar to what has been suggested for circulating
plasma CD36 for type 2 diabetes prediction27.
In conclusion, MCC-Seq provides high-resolution and
cost-effective interrogation of functional methylomes in disease-
relevant tissues with concurrent genotyping of potentially
millions of SNPs. With its customizable panel design, our
approach permits ﬂexibility in both size and regions, to be
interrogated for disease-associated epigenetic variant discovery.
Our results demonstrate the signiﬁcant utility of the approach
over WGBS, Illumina 450K array and Agilent SureSelect
methods. We demonstrate that targeting active regulatory regions
for disease-associated DNA methylation CpG investigation is a
valid strategy over whole-genome investigation. Our data suggest
that applying MCC-Seq in large cohorts will be a powerful
approach to identify trait-associated methylation in studies of
human disease.
Methods
First-generation panel design. We designed a ﬁrst-generation capture panel
(Met V1) targeting the functional methylome in human AT. Regions incorporated
in the panel design included hypomethylated windows generated from merged
WGBS data from 30 subcutaneous AT samples derived from the MuTHER/
TwinsUK cohort3. Brieﬂy, the mean methylation levels per CpG were kept for
those detected in at least 3 individuals resulting in 15,462,376 CpGs.
We then calculated the probability of obtaining the speciﬁc methylation level
(excluding complete hypomethylation corresponding to 0%) per CpG in our
merged data set. The probabilities were then merged for three, four, ﬁve and ten
consecutive CpGs within a window of 1 kb. As the majority of CpGs are
hypermethylated with a mean methylation of B80%, hypomethylated windows
corresponded to small probability estimates. Based on these probabilities, we then
selected the bottom 2% of the different windows generated for inclusion in the Met
V1 panel design.
Next, AT-speciﬁc regulatory elements were incorporated into the panel design.
Regulatory elements (H3K4me1 and H3K4me3) from AT nuclei derived from ﬁve
independent donors were downloaded from the NIH Roadmap Epigenomics
Project as follows3,28. Aligned ChIP-Seq reads (BAM ﬁles) of the H3K4me1 and
H3K4me3 marks, as well as the ChIP-Seq input, were downloaded from the
NIH Roadmap Epigenomics Project (GEO repository accessions GSM621425,
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Figure 4 | Top TG-associated CpG mapping to an AT-speciﬁc regulatory region—CD36. The top TG-associated CpG (chr7:80,276,086-80,276,087;
P¼ 1.1 10 9; GLM assuming a binomial distribution; turquoise track) identiﬁed in the discovery cohort maps within an intragenic region of CD36, which
overlaps an AT-unique LMR (black track). Investigation within a population-based cohort (NB650) replicated the epigenetic effect in a nearby 450K array
probes (orange track); mapping to the same regulatory region (cg05917188; P¼ 3.2 10 7; linear mixed model). The methylation status of the latter
probe was also found to be negatively associated to CD36 expression in AT (ILMN_1665132; P¼ 6.7 10 5; linear mixed model, pink track). AT-speciﬁc
expression of the gene was also noted through AT RNA-Seq data (purple track).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8211 ARTICLE
NATURE COMMUNICATIONS | 6:7211 | DOI: 10.1038/ncomms8211 | www.nature.com/naturecommunications 7
& 2015 Macmillan Publishers Limited. All rights reserved.
GSM669908, GSM669975, GSM670045, GSM772757, GSM621435, GSM669925,
GSM669988, GSM669998, GSM670041, GSM621401, GSM669934, GSM669940,
GSM669984 and GSM670043). Each ﬁle of the H3K4me1 and H3K4me3 marks
was segmented into 100 bp bins. Within each bin, the sequence reads were counted.
The bin counts were divided by the total number of sequence reads to obtain
normalized intensity signals. ChIP-Seq input reads were processed in the same way
and their normalized signal intensity values were subsequently subtracted from the
normalized bin intensity signals. The H3K4me1 and H3K4me3 bins were then
ranked according to these values. Based on the mean ranking across the ﬁve
individuals, the top 1% bins per histone mark were then included in the panel
design.
Finally, 53,638 Illumina 450K array probes with CpGs showing association
(per-trait Bonferroni Po0.05; nominal Po1.4.0 10 7) to metabolic phenotypes
(for example, BMI, total cholesterol, HDL-C, LDL-C and total TGs) were selected
for inclusion in the Met V1 panel design (Supplementary Data 1). These
associations were identiﬁed through an analysis of Ilumina 450K array AT
methylation data collected from 648 female twins from the MuTHER/TwinsUK
resource3.
In total, 79.6Mb of sequence was targeted. Roche NimbleGen R&D was
responsible for probe design. Each targeted region was extended to a minimum size
of 100 bp and the capture probes were extended beyond the edge of each target to
assure coverage yielding a total of 87.3Mb of sequence in the ﬁnal panel, which
covered 99.2% of our input sequence (Supplementary Data 6). Only 978 of our
selected targets failed in the custom probe design. In total, the Met V1 panel
targeted 2,496,975 CpGs of which 210,883 overlapped with Illumina 450K array sites.
Generation of second-generation panel. The second-generation panel for
adipose methylome capture (Met V2) was designed to cover 131Mb including
extension to 100 bp and additional ﬂanking regions. We identiﬁed and incorpo-
rated into the panel design AT hypomethylated regions as described under
‘Identiﬁcation of hypomethylated regions’. Inclusion was limited to UMRs below a
size of 7,000 bp and LMRs above 100 bp (excluding two large outliers;
Supplementary Data 2). Selected hypomethylated regions covered 2,213,942
and 469,962 CpGs for UMRs and LMRs, respectively. Similar as in Met V1,
AT regulatory regions were also incorporated into the panel design, selecting the
677,809 and 1,327,121 CpGs from the top 1% bins of regulatory elements
(H3K4me1 and H3K4me3) characterized in human adipocytes by the NIH
Epigenome Roadmap consortium as described above. Furthermore, we included all
482,421 CpGs on the Illumina 450K array and all 256,327 SNPs from the Illumina
HumanCore SNPs. Finally, we selected 28,947 metabolic disease GWAS SNPs from
the GWAS catalogue for inclusion into the panel design.
We merged all selected regions using the R/Bioconductor package
GenomicRanges. Roche NimbleGen generated a 156.2-Mb panel based on our
regions, covering 97.9% of our original targeted sequences in 629,845 regions
(Supplementary Data 7). Summary of the generated panel indicated that that
16,759 of our original targets were unsuccessfully covered by the custom probes.
We determined that the maximum CpG coverage capacity of the Met V2 panel is
4,442,383 CpGs.
MCC-Seq protocol. The MCC-Seq protocol was developed and optimized in
collaboration with Roche NimbleGen R&D. Brieﬂy, in MCC-Seq a whole-genome
sequencing library is prepared and bisulﬁte converted, ampliﬁed and a capture
enriching for targeted bisulﬁte-converted DNA fragments is carried out. The
captured DNA is further ampliﬁed and sequenced. More speciﬁcally, whole-
genome sequencing libraries were generated from 700 to 1,000 ng of genomic DNA
spiked with 0.1% (w/w) unmethylated l DNA (Promega) previously fragmented to
300–400 bp peak sizes using the Covaris focused-ultrasonicator E210. Fragment
size was controlled on a Bioanalyzer DNA 1000 Chip (Agilent) and the KAPA
High Throughput Library Preparation Kit (KAPA Biosystems) was applied. End
repair of the generated dsDNA with 30- or 50-overhangs, adenylation of 30-ends,
adaptor ligation and clean-up steps were carried out as per KAPA Biosystems’
recommendations. The cleaned-up ligation product was then analysed on a
Bioanalyzer High Sensitivity DNA Chip (Agilent) and quantiﬁed by PicoGreen
(Life Technologies). Samples were then bisulﬁte converted using the Epitect Fast
DNA Bisulﬁte Kit (Qiagen), according to the manufacturer’s protocol. Bisulﬁte-
converted DNA was quantiﬁed using OliGreen (Life Technologies) and, based on
quantity, ampliﬁed by 9–12 cycles of PCR using the Kapa Hiﬁ UracilþDNA
polymerase (KAPA Biosystems), according to the manufacturer’s protocol. The
ampliﬁed libraries were puriﬁed using Ampure Beads and validated on Bioanalyzer
High Sensitivity DNA Chips, and quantiﬁed by PicoGreen.
Next, SeqCap Epi Enrichment System protocol (Roche NimbleGen) was carried
out for the capture. The hybridization procedure of the ampliﬁed bisulﬁte-
converted library was performed as described by the manufacturer, using 1 mg of
total input of library, which was evenly divided by the libraries to be multiplexed,
and incubated at 47 C for 72 h. Washing and recovering of the captured library, as
well as PCR ampliﬁcation and ﬁnal puriﬁcation, were carried out as recommended
by the manufacturer. Quality, concentration and size distribution of the captured
library was determined by Bioanalyzer High Sensitivity DNA Chips. Each capture
was sequenced on the Illumina HiSeq2000/2500 system using 100 bp paired-end
sequencing.
MCC-Seq methylation proﬁling. Reads were aligned to the bisulﬁte-converted
reference genome using BWA v.0.6.1 (ref. 13). We removed the following: (i) clonal
reads, (ii) reads with low mapping quality score (o20), (iii) reads with 42%
mismatch to converted reference over the alignment length, (iv) reads mapping on
the forward and reverse strand of the bisulﬁte-converted genome, (v) read pairs not
mapped at the expected distance based on library insert size and (vi) read pairs that
mapped in the wrong direction as described by Johnson et al.29. To avoid potential
biases in downstream analyses, CpGs were further ﬁltered as follows: CpGs not
covered by at least ﬁve reads, CpGs not covered by at least two reads per strand,
CpGs overlapping an SNP (dbSNP 137) and sites overlapping DAC Blacklisted
Regions or Duke Excluded Regions generated by the ENCODE project:
(http://hgwdev.cse.ucsc.edu/cgi-bin/hgFileUi?db=hg19&g=wgEncodeMapability).
We further selected CpGs sites that exhibited r20% methylation difference
between strands. Finally, all off-target reads were removed. Methylation values at
each site were calculated as total (forward and reverse) non-converted C-reads over
total (forward and reverse) reads. CpGs were included in subsequent analysis if the
number of sequence reads was ﬁve or greater. In some analyses, we also excluded
sites at which the average sequence depth over all study individuals was below the
20th percentile in the complete data set. CpGs were counted once per location
combining both strands together.
Illumina 450K array methylation proﬁling. Bisulﬁte conversion was conducted
on 1 mg of a subset of 24 VAT DNA samples and quantitative DNA methylation
analysis was carried out at the McGill University and Ge´nome Que´bec Innovation
Centre (Montreal, Canada). Inﬁnium HumanMethylation450 BeadChip (Illumina)
was processed according to the manufacturer’s instructions. Methylation data
were visualized and analysed using the GenomeStudio software version 2011.1
(Illumina) and the Methylation Module. None of the samples were excluded
following quality control steps assessed by bisulﬁte conversion, extension, staining,
hybridization, target removal, negative and nonpolymorphic control probes.
Methylation levels (b-values) were estimated as the ratio of signal intensity of the
methylated alleles to the sum of methylated and unmethylated intensity signals of
the alleles (b-value¼C/(TþC)). The b-values vary from 0 (no methylation) to
1 (100% methylation). Methylation b-values were further quantile normalized
to remove unwanted technical variation, using control probes as recently
presented17.
Agilent SureSelect CpG proﬁling and MCC-Seq comparisons. An MCC-Seq
panel (Roche NimbleGen) was designed to mimic the SureSelect Human Methyl-
Seq panel (Agilent) by designing probes against the same genomic coordinates, but
targeting both DNA strands. As the MCC-Seq protocol hybridizes probes to library
fragments after bisulﬁte treatment and PCR ampliﬁcation, when the sequences of
those fragments may be highly variable depending on the CpG density and initial
methylation status of each CpG within each original DNA molecule, multiple
probes with different sequences were designed to permit effective hybridization
capacity over the full range of possible post-bisulﬁte sequences. The MCC-Seq and
SureSelect Methyl-Seq capture experiments were executed at Roche NimbleGen
(Madison, WI), while the SureSelect Methyl-Seq captures and sequencing were
performed by a third-party service provider, according to manufacturer’s
instructions, using 1 mg (MCC-Seq) or 3 mg (SureSelect) of DNA extracted from the
LCL GM12878 cell line.
MCC-Seq reads were ﬁltered according to our bioinformatics pipeline described
above (MCC-Seq methylation proﬁling). Given the single-strand bias of the Agilent
method, no ﬁlters were applied on the Agilent SureSelect data. Comparisons of the
methylation calls from both methods were made for overlapping sites at Z5X
(N¼ 2,551,186 CpGs) and at Z10X (N¼ 2,496,975 CpGs).
Trait-association discovery cohort. Between June 2000 and July 2012, 1,906
severely obese men (N¼ 597) and women (N¼ 1,309) undergoing biliopancreatic
diversion with duodenal switch30 at the Quebec Heart and Lung Institute (Quebec
City, Quebec, Canada) were recruited. Subjects had fasted overnight before the
surgical procedure. Anaesthesia was induced by a short-acting barbiturate and
maintained by fentanyl and a mixture of oxygen and nitrous oxide. VAT samples
were obtained within 30min of the beginning of the surgery from the greater
omentum31. Here, a subset of the VAT cohort was included corresponding to 72
individuals (BMI440 kgm 2; discovery cohort) free of metabolic diseases such as
type 2 diabetes, cardiomyopathy, or endocrine disorders. Thirty-ﬁve individuals
were deemed to have metabolic syndrome (MetSþ group), while the remaining 37
were not affected (MetS group). The presence of MetS was determined by the
National Cholesterol Education Program Adult Treatment Panel III guidelines
when an individual fulﬁlled three or more criteria15. None of the study
participations was on medication to treat MetS features. The sample collection of
AT was approved by the Universite´ Laval and McGill University (IRB
FWA00004545) ethics committee and performed in accordance with the principles
of the Declaration of Helsinki. Tissue banking and the severely obese cohort were
approved by the research ethics committees of the Quebec Heart and Lung
Institute. All participants provided written informed consent before enrolment
in the study.
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Body weight, height, waist girth and resting systolic and diastolic blood pressure
were measured preoperatively by standardized procedures. BMI was calculated as
weight in kilograms divided by height in metres squared. Plasma total cholesterol
(total-C), TG and HDL-C levels were measured using enzymatic assays. HDL-C
was measured in the supernatant following precipitation of very-low-density
lipoproteins and low-density lipoproteins with dextran sulphate and magnesium
chloride. Plasma LDL-C levels were estimated with the Friedewald formula. Fasting
glucose concentrations were enzymatically measured32.
DNA isolation. Genomic DNA was extracted from 200mg of all 72 VAT
samples using the DNeasy Blood & Tissue kit (Qiagen), as recommended by the
manufacturer, and quantiﬁed using both NanoDrop Spectrophotometer (Thermo
Scientiﬁc) and PicoGreen DNA methods.
Identiﬁcation of hypomethylated regions. We merged WGBS data from 30
healthy individuals, ﬁltered as described under ‘MCC-Seq methylation proﬁling’, to
deﬁne AT-speciﬁc hypomethylated regulatory regions. A minimum of three indi-
viduals per CpG was set as a threshold for inclusion into the merged set. We
applied the R/Bioconductor package MethylSeekR to the data set, to identify and
deﬁne regulatory regions as LMRs and UMRs. Brieﬂy, this package uses a cutoff
method wherein UMRs and LMRs are predicted at single-base resolution as regions
of consecutive CpGs having methylation statuses under a set level with UMRs
being differentiated from LMRs based on a minimum content of 30 CpGs16. By
default, a methylation threshold of 50% and false-discovery rate of 5% was set for
the analysis16, ﬁxing consecutive CpGs at Z4. We identiﬁed 20,195 UMRs and
45,065 LMRs for AT. The same procedure was carried out in WGBS data collected
from whole-blood samples of the same cohort, identifying 19,871 UMRs and
46,159 LMRs. We intersected the AT and whole-blood hypomethylated regions
and found 2,342 and 24,687 AT-unique UMRs and LMRs, respectively.
Genotyping. The same samples (N¼ 24) included for Illumina 450K methylation
proﬁling were also selected for high-density genotyping using the Illumina
HumanOmni2.5-8 (Omni2.5) BeadChip according to protocols recommended by
Illumina. After applying quality control ﬁlters, genotypes were retrained for
2,132,665 SNP sites. Simultaneous genotypes calls from MCC-Seq data (Met V1)
were inferred using the Bis-SNP33 software, a bisulﬁte-sequencing variant
caller, with default parameters: ‘-T BisulﬁteGenotyper -stand_call_conf 20
-stand_emit_conf 0 -mmq 30 -mbq 17 -minConv 0’ and with dbSNP 137 as prior
SNP information. The aligned bam ﬁles were used as input ﬁle and the hg19 was
used as the reference genome. These genotypes were then compared with the
genotypes from HumanOmni-2.5M genotyping data.
Epigenome-wide association of TG levels. Associations of methylation levels of
CpGs detected in VAT (N¼ 72) with TG levels were tested using a GLM function
implemented in R3.1.1. Two outliers in TG levels were identiﬁed by setting a cutoff
of mean±3*s.d. and removed from any further analysis. The response variable
(methylation levels) was ﬁtted to a binomial distribution weighted for sequence
read coverage at each site and adjusted for age, sex and BMI. All CpGs associated
with TG at Po0.05 were subjected to permutation tests, to establish the sig-
niﬁcance of phenotype effect as follows: the DNA methylation values for each CpG
were permuted 10,000 times and the GLM was ﬁtted at each permutation round.
Permutation P-values were established by counting how many times the permuted
association resulted in signiﬁcance smaller than the observed GLM P-value for each
CpG. Replication of the 2,580 MCC-Seq TG-associated CpGs with permutation
Pr0.001 was conducted in AT methylation data from an independent cohort of
648 female individuals in the MuTHER cohort. Associations between Illumina
450K array methylation data and TG levels were assessed using a linear mixed
model taking into account familial relationship, twin zygosity and other cofactors
(that is, age, beadchip, bisulﬁte conversion efﬁciency and bisulﬁte-treated DNA
input) and summary statistics were obtained from http://www.sanger.ac.uk/
resources/software/genevar/. Expanding to 250 bp ﬂanking regions around MCC-
Seq TG-associated sites, we were able to assess replication status in 1,582 sites.
Expression QTL data available from this same cohort was further used to validate
the TG association established within the MCC-Seq data at the CD36 loci (http://
www.sanger.ac.uk/resources/software/genevar/).
Adipocyte nuclei isolation. Subcutaneous and visceral adipose tissues were col-
lected from obese individuals undergoing biliopancreatic diversion with duodenal
switch. Mature adipocytes were isolated as follows34: freshly sampled adipose
tissues were minced and digested in Krebs Ringer Henseleit Buffer (1M HEPES,
2M NaCl, 1M KCl, 1M CaCl2, 1M MgCl2, 1M K2HPO4, pH 7.4) supplemented
with 5mM glucose, 0.1 mM adenosine, 0.1mgml 1 ascorbic acid, 4%
electrophoresis grade, delipidated BSA and 350Uml 1 collagenase (Worthington
Biochemical Corp., Lakewood, NJ) for 45min with agitation (37 C). Adipocyte
suspensions were ﬁltered through nylon mesh and washed with the buffer. Isolated
adipocytes were homogenized in two volumes of lysis buffer (25mM Tris pH 7.5,
5mM MgCl2, 0.5% Triton X-100, 0.3M sucrose and protease inhibitors) for 2min
on ice, then centrifuged at 3,220g for 25min (4 C). The pellets were washed
twice with lysis buffer and resuspended in nuclei storage buffer (50mM Tris
pH 7.8, 5mM MgCl2, 0.1mM EDTA, 0.1mM dithiothreitol, 40%v/v glycerol)
for freezing.
Transposase-accessible chromatin sequencing. ATAC-Seq libraries were
generated on 100,000 mature adipocyte nuclei using a modiﬁed protocol to that
published recently20. More precisely, transposase reaction was carried out for
30min at 37 C in a 25-ml reaction volume using 10X transposase concentration
(Illumina Nextera Kit). EDTA (25mM) was added to the reaction mix and
transferred to ice before recovering DNA using MinElute PCR Puriﬁcation
columns (Qiagen). Next, samples were PCR enriched (ten cycles; Supplementary
Table 6) and DNA was isolated using GeneRead Puriﬁcation columns (Qiagen).
Libraries were quantiﬁed by quantitative PCR (Supplementary Table 7), Picogreen
and LabChip, then were sequenced on the Illumina HiSeq2500 pair-ended 100 bp,
using the Nextera sequencing primers.
Raw reads were trimmed for quality (phred33 Z30) and length (nZ32), and
Illumina adapters were clipped off using Trimmomatic v. 0.22 (ref. 35). Filtered
reads were aligned to the hg19 human reference using BWA v.0.6.1 (ref. 13). Peaks
were called without a control using MACS v. 2.0.10.07132012 (ref. 36) at a q-value
cutoff of 0.05.
Blood cell isolation. Peripheral blood mononuclear cells were puriﬁed from buffy
coats originating from 450ml blood of healthy blood donors (Uppsala Blood
Transfusion Center, Uppsala University Hospital, Sweden), using Ficoll-Paque
(GE Healthcare) density-gradient centrifugation. B cells, T cells and monocytes
were isolated from dedicated batches of peripheral blood mononuclear cells, using
positive selection with CD19þ , CD3þ and CD14þ beads (Miltenyi Biotec),
respectively, according to the manufacturer’s instructions.
RNA sequencing. RNA isolations was performed using miRNeasy Mini Kit
(Qiagen). RNA library preparations were carried out on 500 ng of RNA with RNA
integrity number (RIN)47 isolated from adipocyte cells extracted from AT37,38
and blood cells (CD19þ , CD3þ and CD14þ ) using the Illumina TruSeq
Stranded Total RNA Sample preparation kit, according to manufacturer’s protocol.
Final libraries were analysed on a Bioanalyzer and sequenced on the Illumina
HiSeq2000 (pair-ended 100 bp sequences). Raw reads were trimmed for quality
(phred33Z30) and length (nZ32), and Illumina adapters were clipped off using
Trimmomatic v. 0.32 (ref. 35). Filtered reads were aligned to the hg19 human
reference using Tophat v.2.0.10 (ref. 39) and bowtie v.2.1.0 (ref. 40). Raw read
counts of UCSC genes were obtained using htseq-count v.0.6.1 (http://www-
huber.embl.de/users/anders/HTSeq). Differential expression analysis was done
using DESeq41 including adipocytes isolated from AT (subcutaneous and visceral)
of four obese individuals undergoing bariatric surgery and different blood cell types
(B cells, T cells and monocytes) of four healthy individuals (Uppsala Blood
Transfusion Center, Uppsala University Hospital, Sweden).
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